In this respect, animal studies showed that treatment of APP/PS1 AD mice with Edaravone intraperitoneal injection either before or after the onset of Aβ disposition reduced the plaque load in the brain, alleviated OS, and reduced downstream pathologies including neuroinflammation, synaptic dysfunction, and apoptosis, and ameliorated cognitive deficits in AD mice (Jiao, Yao, et al. 2015). Here, APP is linked to Alzheimer disease.